EICHORCondition: Prostate Cancer · Sponsor: Myriad Genetic Laboratories, Inc.
This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients with Prolaris low-risk scores without negatively impacting patient oncologic outcomes, thereby sparing low-risk patients from unnecessary treatments and associated side-effects.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Urology Centers of Alabama | Homewood, Alabama, United States | — |
| East Valley Urology Center | Mesa, Arizona, United States | — |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | — |
| Arkansas Urology | Little Rock, Arkansas, United States | — |
| Pacific Urology | Concord, California, United States | — |
| VA Long Beach Healthcare | Long Beach, California, United States | — |
| UCI Medical Center | Orange, California, United States | — |
| Ssg Md Apc | San Jose, California, United States | — |
| Advanced Urology Institute | Daytona Beach, Florida, United States | — |
| Urology Group of Florida | Delray Beach, Florida, United States | — |
| Pinellas Urology | St. Petersburg, Florida, United States | — |
| 21st Century Oncology | Sunrise, Florida, United States | — |
+ 22 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03290508